Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.

MLA

Barbanti, Piero, et al. “Impact of Multiple Treatment Cycles with Anti-CGRP Monoclonal Antibodies on Migraine Course: Focus on Discontinuation Periods. Insights from the Multicenter, Prospective, I-GRAINE Study.” Journal of Neurology, vol. 271, no. 5, May 2024, pp. 2605–14. EBSCOhost, https://doi.org/10.1007/s00415-024-12192-9.

APA

Barbanti, P., Aurilia, C., Egeo, G., Proietti, S., Torelli, P., d’Onofrio, F., Carnevale, A., Tavani, S., Orlando, B., Fiorentini, G., Colombo, B., Filippi, M., Bonassi, S., & Cevoli, S. (2024). Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study. Journal of Neurology, 271(5), 2605–2614. https://doi.org/10.1007/s00415-024-12192-9

Chicago

Barbanti, Piero, Cinzia Aurilia, Gabriella Egeo, Stefania Proietti, Paola Torelli, Florindo d’Onofrio, Antonio Carnevale, et al. 2024. “Impact of Multiple Treatment Cycles with Anti-CGRP Monoclonal Antibodies on Migraine Course: Focus on Discontinuation Periods. Insights from the Multicenter, Prospective, I-GRAINE Study.” Journal of Neurology 271 (5): 2605–14. doi:10.1007/s00415-024-12192-9.